Advair could face competition from generics as early as 2016

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

Advair could face competition from generics as early as 2016

Generics/News | Posted 27/09/2013 0 Post your comment

GlaxoSmithKline’s (GSK) asthma and chronic obstructive pulmonary disorder treatment Advair (fluticasone/salmeterol) could face competition from generics sooner than expected, after FDA issued draft guidance on generics of the drug.

On 9 September 2013, FDA issued draft guidance which would allow generics makers to submit in vitro and in vivo studies and simple bioequivalence trials to prove the drug works the same as Advair, rather than having to carry out long, expensive clinical trials.

Advair, which delivers two drugs to patients orally through an inhaler, is the world’s third best selling drug with revenue of GBP 5 billion (US$8 billion) last year and accounts for about a fifth of GSK’s annual sales. Only AbbVie’s Humira (adalimumab) and Johnson & Johnson’s Remicade (infliximab), biologicals which both treat arthritis, have greater worldwide sales.

Generics companies, including Actavis, Cipla, Mylan, Sandoz, Teva Pharmaceutical Industries and Vectura, are expected to launch generic versions of Advair as soon as 2016.

Until now, GSK and FDA had said that the same drug in a different inhaler was a different product because the device used to administer the medicine can cause dosing to vary. The vast majority of analysts had therefore assumed that ‘true’ generic versions of Advair were not likely to be launched in the US, due to the problem of dosing. While the patent on Advair expired in 2010 in the US, a separate patent on the Diskus device remains in force until 2016.

The draft guidance from FDA lays out the characteristics that an inhaler should have, including a similar size and shape to GSK’s Diskus device.

GSK told Bloomberg that they believed that ‘the manufacture of combination respiratory medicines such as Advair presents significant hurdles and remains extremely challenging.’

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: FDA